

Table SI. Eczema Area and Severity Index scoring system.

Body parts	Proportion of area affected in individuals aged 0-7 years	Proportion of area affected in individuals >8 years of age
Head and neck	x0.2	x0.1
Upper limbs	x0.2	x0.2
Trunk	x0.3	x0.3
Lower limbs	x0.3	x0.4

Values should be interpreted as a fraction representing the proportion of the total body area affected.

Table SII. Dermatology Life Quality Index scoring system.

Problems over the past week	None	Slight	Serious	Very serious
Do you have itchy, tingly skin?				
Do you feel sad, embarrassed or inferior because of your skin problem?				
Does your skin affect your ability to go shopping or do housework?				
Does it affect the way you dress in regard to the clothes or shoes you wear?				
Does the skin problem affect your social interactions, leisure and recreation?				
Does the skin problem affect your sports and exercise?				
Does the skin problem affect your work and study?				
Does the skin problem affect your relationship with family and friends?				
Does the skin problem affect your sex life?				
How much trouble does the skin problem add to your daily routine?				
Total score:				

Table SIII. Patient Oriented Eczema Measure scoring system.

Queries about the effects of the skin issues over the past week	0 days	1-2 days	3-4 days	5-6 days	Every day
How many days did itching occur due to atopic dermatitis?					
How many days has sleep been affected by atopic dermatitis?					
How many days did atopic dermatitis cause skin bleeding?					
On how many days did atopic dermatitis cause oozing (clear or yellowish fluid) from the skin?					
On how many days did atopic dermatitis result in cracked (dry) skin?					
On how many days did atopic dermatitis cause the skin to flake (peel)?					
On how many days did the skin feel dry or rough due to atopic dermatitis?					
Total score:					

Table SIV. ADCT scoring system.

Question	Frequency over the past week				
	None	Mild	Moderate	Severe	Very severe
How would you rate the current skin condition-related symptoms (e.g., itching, dry skin or rash)?	None	Mild	Moderate	Severe	Very severe
On how many days have you had a series of itching episodes due to this condition?	None	1-2 days	3-4 days	5-6 days	Every day
How many nights have you been unable to sleep or have had trouble sleeping due to the condition?	None	1-2 days	3-4 days	5-6 days	Every day
How much discomfort does the condition cause you?	None	Slight	Moderate	Very	Extremely
How much does the condition affect your daily activities?	None	Slight	Moderate	Very	Extremely
How much does the condition affect your mood or emotions?	None	Slight	Moderate	Very	Extremely
Total score:					

Table SV. Clinical scores of patients with atopic dermatitis treated with dupilumab.

Score	Week 0	Week 2	Week 4	Week 8
Eczema Area and Severity Index	8.9 (6.2, 21.7)	6.9 (4.4, 12.1)	3.4 (2.3, 11.0)	1.3 (0.7, 5.8)
Objective-SCORAD	37.0 (23.4, 48.0)	35.3 (22.9, 36.5)	19.3 (12.3, 32.0)	11.2 (7.2, 24.2)
SCORAD	46.6 (36.4, 53.5)	36.2 (28.9, 42.0)	23.5 (14.3, 29.5)	21.9 (8.4, 41.8)
Itch Numeric Rating Scale	6.0 (4.5, 9.5)	3.0 (3.0, 6.0)	3.0 (2.0, 3.5)	2.0 (1.5, 3.5)
Dermatology Life Quality Index	10.0 (9.0, 16)	6.0 (5.0, 12.0)	5.0 (3.0, 7.5)	3.0 (2.0, 7.5)
Patient-oriented Eczema Measure	14.0 (11.5, 23.5)	10.0 (7.0, 11.5)	6.0 (5.0, 11.0)	8.0 (2.5, 11.5)
Atopic Dermatitis Control Tools	12.0 (10.5, 19.0)	10.0 (6.5, 11.0)	7.0 (5.5, 9.0)	7.0 (3.0, 10.5)

SCORAD: Scoring Atopic Dermatitis index. Each index was non-normally distributed and presented as the median and interquartile range (1st quartile, 3rd quartile).

Table SVI. Levels of serum biomarkers of patients with atopic dermatitis treated with dupilumab.

Biomarker (pg/ml)	Week 0	Week 2	Week 4	Week 8
Thymus and activation-regulated chemokine				
X ± SD	511.91±457.52	251.68±298.98	148.35±286.50	148.35±286.50
M (Q ₁ , Q ₃)	450.46 (100.13, 822.33)	237.69 (68.84, 519.43)	151.82 (42.32, 209.38)	151.82 (42.32, 209.38)
Human β-defensin 2				
X ± SD	1,010.06±1,093.78	1,044.29±1,215.23	450.17±739.45	764.25±1,391.72
M (Q ₁ , Q ₃)	573.47 (269.98, 2712.11)	544.16 (452.58, 996.48)	192.55 (105.46, 655.94)	455.84 (140.38, 1,958.41)
IgE against <i>Staphylococcus aureus</i> enterotoxin A				
X ± SD	10.57±12.63	9.84±11.34	10.18±11.85	10.46±11.87
M (Q ₁ , Q ₃)	5.51 (5.22, 6.24)	5.62 (5.53, 6.17)	5.66 (5.28, 6.52)	6.08 (5.37, 6.72)

X, mean; M, median; Q₁, 1st quartile; Q₃, 3rd quartile.

Table SVII. Proportion of circulating Th1, Th2, Th17 and Th22 cells in patients with atopic dermatitis treated with dupilumab.

Proportion of Th cells (%)	Week 0	Week 2	Week 4	Week 8
Th1				
X ± SD	13.38±9.11	10.77±6.20	12.31±6.80	10.92±7.01
M (Q ₁ , Q ₃)	11.70 (3.70, 21.0)	9.60 (4.30, 17.60)	7.50 (6.30, 21.10)	10.23 (5.50, 19.00)
Th2				
X ± SD	6.14±4.79	8.73±4.49	5.46±3.39	6.44±5.82
M (Q ₁ , Q ₃)	4.40 (2.50, 9.90)	6.50 (3.90, 13.10)	4.50 (2.00, 12.50)	3.20 (1.90, 11.20)
Th17				
X ± SD	0.36±0.34	0.38±0.31	0.38±0.23	0.25±0.09
M (Q ₁ , Q ₃)	0.20 (0.10, 0.60)	0.10 (0.10, 0.90)	0.30 (0.10, 0.60)	0.30 (0.10, 0.30)
Th22				
X ± SD	0.24±0.19	0.38±0.28	0.87±0.83	0.57±0.92
M (Q ₁ , Q ₃)	0.20 (0.10, 0.60)	0.20 (0.10, 0.50)	0.30 (0.10, 1.10)	0.10 (0.10, 0.20)
Th2/Th1 ratio				
X ± SD	0.80±0.70	1.73±2.52	0.80±0.81	0.86±1.00
M (Q ₁ , Q ₃)	0.30 (0.19, 2.64)	0.66 (0.26, 1.86)	0.33 (0.21, 1.11)	0.31 (0.21, 1.42)

Th, T helper; X, mean; M, median; Q₁, 1st quartile; Q₃, 3rd quartile.